antisense oligonucleotide therapy
/ Sarepta Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 26, 2023
Using antisense oligonucleotide therapy to rescue dystrophin (DMD) in the central nervous system in the mdx23 mouse model of Duchenne muscular dystrophy
(WMS 2023)
- No abstract available
Preclinical • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy
1 to 1
Of
1
Go to page
1